AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding the number of calcifications to the model with age, pack‐years, smoking status, and modified Agatston score strata
Number of subjects: 3559
Study 25533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of the largest calcification
Number of subjects: 3559
Study 22882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Start For Life treatment (30 minutes daily of structured physical activity with behavioral and self-regulatory skills training)
Number of subjects: 338
Study 22882084 — intervention group
Group type: EXPERIMENTAL
Intervention: Start For Life treatment
Number of subjects: 338
Study 22882084 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control condition
Number of subjects: 338
Study 21598057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target 4.4‐6.1 mmoL·L(‐1) or 80‐110 mg·dL(‐1))
Number of subjects: 364
Study 21598057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 364
Study 21598057 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control (target 10‐11.1 mmoL·L(‐1) or 180‐200 mg·dL(‐1))
Number of subjects: 364
Study 19349306 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode psychosis (FEP)
Number of subjects: 80
Study 19349306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-risk individuals (UHRP)
Number of subjects: 80
Study 19349306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-risk individuals (UHRP) and first-episode psychosis (FEP)
Number of subjects: 80
Study 19349306 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 80
Study 19349306 — intervention group
Group type: COMPARATOR
Intervention: Ultrahigh-risk non-psychotic individuals (UHRNP)
Number of subjects: 80
Study 16685055 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk (71.6 mg isoflavones from 706 mL soymilk/d)
Number of subjects: 52
Study 16685055 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement (70 mg isoflavones in a supplement plus 706 mL cow milk/d)
Number of subjects: 52
Study 16685055 — intervention group
Group type: COMPARATOR
Intervention: Control (706 mL cow milk/d plus a placebo supplement)
Number of subjects: 52
Study 15300729 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave stimulation (450 MHz, 7 Hz on‐off modulation, 0.16 mW/cm2)
Number of subjects: 20
Study 15300729 — intervention group
Group type: EXPERIMENTAL
Intervention: Photic stimulation
Number of subjects: 20
Study 11780680 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) 60 mg orally twice daily for 12 weeks
Number of subjects: 83
Study 11780680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 9871866 — intervention group
Group type: EXPERIMENTAL
Intervention: Topographic parameters computed by the HRT
Number of subjects: 225
Study 9871866 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis of topometric parameters
Number of subjects: 225
Study 9871866 — intervention group
Group type: EXPERIMENTAL
Intervention: Interocular differences in topographic parameters
Number of subjects: 225
Study 8030848 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonic-Stress (AS)
Number of subjects: 343
Study 8030848 — intervention group
Group type: COMPARATOR
Intervention: Meclofenoxate (MF)
Number of subjects: 343
Study 8030848 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline (NE)
Number of subjects: 343
Study 8030848 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 343
Study 2643038 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 47
Study 2643038 — intervention group
Group type: COMPARATOR
Intervention: Sham sphincterotomy
Number of subjects: 47
Study 2643038 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 47
Study 30531312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 60
Study 30531312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28225508 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a suicide attempt within the last 3 months
Number of subjects: 228
Study 28225508 — intervention group
Group type: COMPARATOR
Intervention: Patients with suicidal thoughts but no attempts
Number of subjects: 228
Study 25167840 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168 50μg
Number of subjects: 50
Study 25167840 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168 100μg
Number of subjects: 50
Study 25167840 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168 200μg
Number of subjects: 50
Study 25167840 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168 300μg
Number of subjects: 50
Study 25167840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25167840 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX168
Number of subjects: 50
Study 23453459 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/day for 14 days)
Number of subjects: 30
Study 23453459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23453459 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 30
Study 23453459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 30
Study 21642851 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc) patients
Number of subjects: 37
Study 21642851 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 37
Study 21642851 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SSc patients and control subjects
Number of subjects: 37
Study 18371034 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy (bovine lung surfactant extract) with standard treatment for RDS
Number of subjects: 27
Study 18371034 — intervention group
Group type: COMPARATOR
Intervention: Standard care for RDS without surfactant therapy
Number of subjects: 27
Study 16423747 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pre-event stereotype
Number of subjects: 0
Study 16423747 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative misinformation
Number of subjects: 0
Study 16423747 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection for negative misinformation
Number of subjects: 0
Study 16423747 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity for positive misinformation
Number of subjects: 0
Study 14519175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (sustained-release)
Number of subjects: 600
Study 14519175 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol smokers
Number of subjects: 600
Study 10949981 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg once-daily for 5 days)
Number of subjects: 600
Study 10949981 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three-times daily for 7 days)
Number of subjects: 600
Study 10949981 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 600
Study 10949981 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 600
Study 9171971 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) and resistance exercise
Number of subjects: 11
Study 9171971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9171971 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-training after 12 weeks of detraining
Number of subjects: 11
Study 8160567 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (T)
Number of subjects: 9
Study 8160567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 3769187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (0.24 mg/kg/hr)
Number of subjects: 40
Study 3769187 — intervention group
Group type: COMPARATOR
Intervention: No dipyridamole (control group)
Number of subjects: 40
Study 29440219 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratin dressings
Number of subjects: 0
Study 29440219 — intervention group
Group type: COMPARATOR
Intervention: Usual care non-medicated dressings
Number of subjects: 0
Study 29071914 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zigong (EX-CA 1) and Tianshu (ST 25) combined with manual acupuncture at Sanyinjiao (SP 6) and Guanyuan (CV 4) for 8 weeks (30 min, 10 Hz/50 Hz, 3 times a week).
Number of subjects: 58
Study 29071914 — intervention group
Group type: COMPARATOR
Intervention: Medication group receiving estradiol valerate (1 mg/day for 3 weeks, followed by a week of rest, then 1 mg/day and medroxyprogesterone 17-acetate (8 mg/day) for 10 days).
Number of subjects: 58
Study 29071914 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (EA and manual acupuncture).
Number of subjects: 58
Study 24103107 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 170
Study 24103107 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 170
Study 24103107 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 170
Study 24103107 — intervention group
Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 170
Study 22233103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation intervention
Number of subjects: 238
Study 22233103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mental simulation and implementation intention intervention
Number of subjects: 238
Study 22233103 — intervention group
Group type: COMPARATOR
Intervention: No mental simulation
Number of subjects: 238
Study 22233103 — intervention group
Group type: COMPARATOR
Intervention: No implementation intention
Number of subjects: 238
Study 19666118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) plus Pitavastatin (2mg/day)
Number of subjects: 20
Study 19666118 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin (2mg/day) alone
Number of subjects: 20
Study 18602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitespen (HSPPC-96); administered intradermally once a week for 4 weeks, then every 2 weeks until vaccine depletion
Number of subjects: 728
Study 18602688 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 728
Study 18602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitespen (HSPPC-96); administered intradermally
Number of subjects: 728
Study 18602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitespen (HSPPC-96)
Number of subjects: 728
Study 16007029 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (n=22)
Number of subjects: 40
Study 16007029 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n=18)
Number of subjects: 40
Study 12192554 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with doses of 150 Gy
Number of subjects: 224
Study 12192554 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with doses of 300 Gy
Number of subjects: 224
Study 12192554 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with target dose of 256 Gy
Number of subjects: 224
Study 12192554 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 224
Study 10353922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk (FHM, n = 62)
Number of subjects: 108
Study 10353922 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula (PF, n = 46)
Number of subjects: 108
Study 8610612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once daily
Number of subjects: 54
Study 2010374 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at various intensities and durations (30 min at 65% VO2max, 60 min at 30% VO2max, 60 min at 75% VO2max, 120 min at 65% VO2max)
Number of subjects: 0
Study 2010374 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exercise intensity in the highly fit group
Number of subjects: 0
Study 2010374 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 0
Study 7028260 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 alone (group 1)
Number of subjects: 118
Study 7028260 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 combined with cyclophosphamide (group 2)
Number of subjects: 118
Study 7028260 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 combined with doxorubicin (group 3)
Number of subjects: 118
Study 31009768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm allograft bone particles (ABP) augmentation in groups A1 and A2
Number of subjects: 60
Study 31009768 — intervention group
Group type: EXPERIMENTAL
Intervention: Full (100%) trajectory augmentation with 1 mm ABP in groups B1 and B2
Number of subjects: 60
Study 31009768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm ABP vs 2 mm ABP in groups C1 and C2
Number of subjects: 60
Study 28272197 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed standing exercises and assisted standing for more than 2 hours a day, more than 5 days a week
Number of subjects: 12
Study 28272197 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy with a standing program for 20 minutes a day, 2 to 3 days a week
Number of subjects: 12
Study 28272197 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 12
Study 26076989 — intervention group
Group type: COMPARATOR
Intervention: Chocolate consumption <1 per month (reference group)
Number of subjects: 18819
Study 26076989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 1 to 3 per month
Number of subjects: 18819
Study 26076989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 2 to 4 per week
Number of subjects: 18819
Study 26076989 — intervention group
Group type: EXPERIMENTAL
Intervention: >5 per week
Number of subjects: 18819
Study 23656493 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TNF-α levels in RM patients during early pregnancy
Number of subjects: 47
Study 23656493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of TNFA -863C and TNFA -1031T polymorphisms
Number of subjects: 47
Study 20163941 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention (L)
Number of subjects: 203
Study 20163941 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 203
Study 20163941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 203
Study 19268676 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 40
Study 19268676 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (Control)
Number of subjects: 40
Study 17711689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina pectoris (SAP) group
Number of subjects: 90
Study 17711689 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery spasm (CAS) group
Number of subjects: 90
Study 17711689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 17711689 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vessel disease group (SAP)
Number of subjects: 90
Study 17711689 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-vessel disease group (SAP)
Number of subjects: 90
Study 15585768 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract supplement
Number of subjects: 30
Study 15585768 — intervention group
Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 30
Study 15585768 — intervention group
Group type: COMPARATOR
Intervention: Green tea
Number of subjects: 30
Study 11723089 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 572
Study 11723089 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (diuretics and/or beta-blockers)
Number of subjects: 572
Study 8995946 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrucel, 1 tablespoon twice daily
Number of subjects: 13
Study 8995946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin, 1 tablespoon twice daily
Number of subjects: 13
Study 8995946 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 13
Study 8515979 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release ibuprofen 600 mg
Number of subjects: 0
Study 8515979 — intervention group
Group type: COMPARATOR
Intervention: Regular ibuprofen 200 mg (3 doses)
Number of subjects: 0
Study 8515979 — intervention group
Group type: COMPARATOR
Intervention: Codeine 30 mg (3 doses)
Number of subjects: 0
Study 3574383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 93
Study 3574383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30809700 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterStim sacral neuromodulation system (treatment group)
Number of subjects: 84
Study 30809700 — intervention group
Group type: COMPARATOR
Intervention: Control group (stimulation delayed for 3 months)
Number of subjects: 84
Study 30032506 — intervention group
Group type: EXPERIMENTAL
Intervention: P15 (15 mmHg)
Number of subjects: 50
Study 30032506 — intervention group
Group type: COMPARATOR
Intervention: P12 (12 mmHg)
Number of subjects: 50
Study 30032506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 26833235 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Closure (NPC)
Number of subjects: 53
Study 26833235 — intervention group
Group type: COMPARATOR
Intervention: Mesh-Mediated Fascial Traction Closure (MMFC)
Number of subjects: 53
Study 25136078 — intervention group
Group type: EXPERIMENTAL
Intervention: BM CD34(+) cell percentage
Number of subjects: 280
Study 25136078 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-derived endothelial colonies
Number of subjects: 280
Study 25136078 — intervention group
Group type: EXPERIMENTAL
Intervention: BM CD11b(+) cells
Number of subjects: 280
Study 25136078 — intervention group
Group type: EXPERIMENTAL
Intervention: BM CD34(+) percentage
Number of subjects: 280
Study 22463388 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (participants who participated in a speech test that increased anxiety and threatened self-esteem)
Number of subjects: 0
Study 22463388 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants not subjected to the stress manipulation)
Number of subjects: 0
Study 19921102 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb-IIIa inhibitors with Drug-Eluting Stents (DES)
Number of subjects: 270
Study 19921102 — intervention group
Group type: COMPARATOR
Intervention: Glycoprotein IIb-IIIa inhibitors with Bare Metal Stents (BMS)
Number of subjects: 270
Study 18570578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (2-8 g/day)
Number of subjects: 306
Study 18570578 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime-amikacin-metronidazole (2-6 g/day, 15 mg/kg/day, 500 mg three times daily)
Number of subjects: 306
Study 18570578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam
Number of subjects: 306
Study 18570578 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime-amikacin-metronidazole
Number of subjects: 306
Study 15845094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion (0.5 M, 5 mL/kg body weight)
Number of subjects: 20
Study 15845094 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl infusion
Number of subjects: 20
Study 12093324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/day)
Number of subjects: 0
Study 12093324 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 12093324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 12093324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 150 mg/day)
Number of subjects: 0
Study 10064170 — intervention group
Group type: COMPARATOR
Intervention: Oral isoprinosine
Number of subjects: 8
Study 10064170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isoprinosine plus intraventricular alpha-interferon
Number of subjects: 8
Study 8756801 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (Sm) 50 micrograms twice daily
Number of subjects: 367
Study 8756801 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Sb) 200 micrograms four times daily
Number of subjects: 367
Study 8756801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 367
Study 1901200 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifater (combined formulation)
Number of subjects: 310
Study 1901200 — intervention group
Group type: COMPARATOR
Intervention: Separate drugs
Number of subjects: 310
Study 6812144 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5HTP) with carbidopa
Number of subjects: 7
Study 6812144 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 7
Study 31449261 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative selection and amplification of sequences starting with a randomized sequence pool; in vitro binding assays
Number of subjects: 0
Study 31449261 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro and in vivo functional assays
Number of subjects: 0
Study 28991149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Outpatient Rehabilitation Treatment (FORT)
Number of subjects: 52
Study 28991149 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment planning
Number of subjects: 52
Study 27256458 — intervention group
Group type: EXPERIMENTAL
Intervention: Preheated skin disinfectant solution (36 °C)
Number of subjects: 220
Study 27256458 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature skin disinfectant solution (20 °C)
Number of subjects: 220
Study 25150038 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions of motivational interviewing and stress management‐relaxation in addition to standard cardiac rehabilitation
Number of subjects: 135
Study 25150038 — intervention group
Group type: COMPARATOR
Intervention: Cardiac rehabilitation alone
Number of subjects: 135
Study 21908049 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the 'Mother‐Infant Transaction Program' (intervention group)
Number of subjects: 214